Completed PHASE3 INTERVENTIONAL 4-arm NCT00115765

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer

Sponsor: Amgen

Conditions Colorectal Cancer

Interventions Bevacizumab Irinotecan Based Chemotherapy Oxaliplatin Based Chemotherapy Panitumumab

Updated 6 times since 2017 Last updated: Sep 20, 2018 Started: Jun 1, 2005 Primary completion: May 31, 2007 Completion: May 1, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Amgen and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Nov 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.